ACIP recommends catch-up HPV vaccines through age 26

ACIP recommends catch-up HPV vaccines through age 26

(HealthDay)—Catch-up human papillomavirus (HPV) vaccinations are recommended for all persons through age 26 years and should be considered for some persons aged 27 to 45 years, according to research published in the Aug. 16 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Noting that HPV vaccination is recommended at age 11 or 12 years, Elissa Meites, M.D., from the CDC in Atlanta, and colleagues updated the Advisory Committee on Immunization Practices (ACIP) catch-up HPV vaccine recommendations and guidance.

The researchers note that routine recommendations for vaccination of adolescents have not changed since the guidelines were published in 2014, 2015, and 2016. For all persons through age 26 years, in June 2019, ACIP recommended catch-up HPV vaccination. For adults aged 27 through 45 years, ACIP did not recommend catch-up vaccination for all, although they did recognize that some persons who are inadequately vaccinated may benefit from vaccination as they are at risk for new HPV infection. For these persons, ACIP recommended shared clinical decision-making for HPV vaccination.

"CDC continues to monitor safety of HPV vaccines and impact of the vaccination program on HPV-attributable outcomes, including prevalences of HPV infections, anogenital warts, cervical precancers, and cancers," the authors write. "ACIP reviews as they become available and updates vaccine policy as needed."

More information: Abstract/Full Text

Copyright © 2019 HealthDay. All rights reserved.

Citation: ACIP recommends catch-up HPV vaccines through age 26 (2019, August 16) retrieved 26 April 2024 from https://medicalxpress.com/news/2019-08-acip-catch-up-hpv-vaccines-age.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Zoster recombinant vaccine provides better value and better protection against shingles

2 shares

Feedback to editors